172 related articles for article (PubMed ID: 23669799)
1. Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol.
Paisansinsup T; Breitenstein MK; Schousboe JT
J Clin Rheumatol; 2013 Jun; 19(4):180-6. PubMed ID: 23669799
[TBL] [Abstract][Full Text] [Related]
2. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
[TBL] [Abstract][Full Text] [Related]
3. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
Yang CY; Chen CH; Deng ST; Huang CS; Lin YJ; Chen YJ; Wu CY; Hung SI; Chung WH
JAMA Intern Med; 2015 Sep; 175(9):1550-7. PubMed ID: 26193384
[TBL] [Abstract][Full Text] [Related]
5. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein AC; Gunter MJ; Lafata JE; Harrold L; Nelson WW; Platt R
Ann Pharmacother; 2006 Mar; 40(3):386-91. PubMed ID: 16478808
[TBL] [Abstract][Full Text] [Related]
6. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
Dalbeth N; Stamp L
Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
[TBL] [Abstract][Full Text] [Related]
8. Relation between adverse events associated with allopurinol and renal function in patients with gout.
Vázquez-Mellado J; Morales EM; Pacheco-Tena C; Burgos-Vargas R
Ann Rheum Dis; 2001 Oct; 60(10):981-3. PubMed ID: 11557658
[TBL] [Abstract][Full Text] [Related]
9. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of allopurinol in chronic kidney disease.
Thurston MM; Phillips BB; Bourg CA
Ann Pharmacother; 2013 Nov; 47(11):1507-16. PubMed ID: 24259601
[TBL] [Abstract][Full Text] [Related]
11. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth N; Kumar S; Stamp L; Gow P
J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol-induced DRESS syndrome in an adolescent patient.
Dewan AK; Quinonez RA
Pediatr Dermatol; 2010; 27(3):270-3. PubMed ID: 19804493
[TBL] [Abstract][Full Text] [Related]
13. A review of inpatients with adverse drug reactions to allopurinol.
Khoo BP; Leow YH
Singapore Med J; 2000 Apr; 41(4):156-60. PubMed ID: 11063179
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?
Lee HY; Ariyasinghe JT; Thirumoorthy T
Singapore Med J; 2008 May; 49(5):384-7. PubMed ID: 18465047
[TBL] [Abstract][Full Text] [Related]
15. Clinical risk factors for adverse events in allopurinol users.
Ryu HJ; Song R; Kim HW; Kim JH; Lee EY; Lee YJ; Song YW; Lee EB
J Clin Pharmacol; 2013 Feb; 53(2):211-6. PubMed ID: 23436266
[TBL] [Abstract][Full Text] [Related]
16. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
17. [Allopurinol-induced hypersensitivity syndrome].
Kinyó A; Lakatos A; Varga A; Gyulai R; Varga E; Bata-Csörgő Z; Kemény L
Orv Hetil; 2012 Apr; 153(15):586-91. PubMed ID: 22472359
[TBL] [Abstract][Full Text] [Related]
18. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
19. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response.
Yun J; Mattsson J; Schnyder K; Fontana S; Largiadèr CR; Pichler WJ; Yerly D
Clin Exp Allergy; 2013 Nov; 43(11):1246-55. PubMed ID: 24152157
[TBL] [Abstract][Full Text] [Related]
20. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
